



## Mergers & Acquisitions

Antitrust Life Sciences and Healthcare Capabilities

### Overview

Baker Botts is widely regarded as a “go-to” firm when it comes to mergers, acquisitions, collaborations, or other transactions in the pharmaceutical, life sciences and healthcare sectors. Our deep bench of talented, experienced lawyers offers insightful and strategic guidance at every stage of the transactional process. We have been granted clearance for hundreds of challenging M&A transactions, including many complex matters initially presumed anticompetitive by relevant authorities. Our team understands the unique transactional issues that surround products and services in these industries, which allows us to help our clients maneuver through regulatory hurdles effectively and efficiently.

Our team works seamlessly across our offices in Washington, Brussels, and around the world in all major jurisdictions, leveraging a base of experience that includes personal appearances before relevant competition authorities. Our team includes numerous former senior competition agency officials who have valuable knowledge of, and relationships with, the antitrust agencies. This experience, coupled with that gleaned from ongoing advocacy efforts before merger control enforcers and policymakers, endows the team with an in-depth understanding of how merger control rules and enforcement are likely to change over the coming months and years.

In an environment in which antitrust is a growing priority for governments – and healthcare and pharmaceutical transactions are a particular priority for antitrust enforcers – such transactions demand experienced counsel who understand the FTC, European Commission and other regulators.

### Representative Experience

- **Boehringer Ingelheim GmbH**, one of the world’s leading pharmaceutical companies focused on researching, developing, and marketing human health and animal health products, in its \$12.6 billion asset swap transaction with Sanofi’s global animal health business
- **OptumCare** in its \$4.3 billion horizontal and vertical acquisitions of physician groups, ambulatory surgery centers, and urgent care clinics in six states
- **Celgene Corporation** on antitrust aspects of its \$74 billion merger with Bristol-Myers Squibb to create a leading focused specialty biopharma company focusing on cancer, inflammatory and immunologic disease, and cardiovascular disease and its acquisition of Juno Therapeutics
- **Kimberly-Clark Corporation** in its \$1.8 billion spin-off of Halyard Health

Austin Brussels Dallas Dubai Houston London  
New York Palo Alto Riyadh San Francisco Singapore Washington

bakerbotts.com | Confidential | Copyright© 2023 Baker Botts L.L.P.

**BAKER BOTTS**

- **Merck & Co.** in various transactions, including its acquisition of rights to Ridgeback Pharmaceutical's COVID-19 anti-viral medicine assets, its \$2.7 billion acquisition of leading cancer drug developer ArQule, and its \$2.2 billion acquisition of biopharmaceutical company Peloton Therapeutics
- **Novartis** in its billion-dollar sale of its generic oral solids and dermatology business to Aurobindo, Inc., and in a number of other potential acquisitions, collaborations, and license agreements
- Leading pet medication and wellness company, **PetIQ**, on its acquisition of Perrigo Animal Health and its \$95 million acquisition of Capstar from Elanco Animal Health
- **OptumRx** in the FTC investigations of its \$12 billion acquisition of PBM Catamaran and its acquisition of specialty workers' compensation PBM Helios, as well as a number of other acquisitions of specialty, online, and institutional pharmacies
- **RWJBarnabas Health** in its acquisition of the Saint Peter's Health Care System and its acquisition of Trinitas acute care facility

## Key Contacts

To learn more about our experience in Litigation, please contact one of the lawyers below.



**Mark J. Botti**

Partner

T: +1.202.639.1116

mark.botti@bakerbotts.com



**Paul Lugard**

Partner

T: +32.2.891.7320

paul.lugard@bakerbotts.com



**Jeffrey S. Oliver**

Partner

T: +1.202.639.7784

jeffrey.oliver@bakerbotts.com